Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524.Which is upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleoside triphosphate that induces RNA chain termination and inhibits viral polymerases.3 Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively).
It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).4 In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.2 Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).4 Formulations containing remdesivir have been used in the treatment of COVID-19.
Remdesivir is a major benefit of remdesivir in comparison with other antiviral nucleoside analogs is its resistance to proofreading exonucleases, which occur in coronaviruses.
WARNING:This product is not for human or veterinary use.
CAS No.ï¼š1770840-43-1 CAS No.ï¼š159326-68-8 CAS No.ï¼š1354823-36-1 CAS No.ï¼š1911578-98-7 CAS No.ï¼š937046-98-5 CAS No.ï¼š946511-97-3